• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Amgen Axes Development of Early-Stage Bispecific T-Cell Engager for Solid Tumors

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 10, 2024 at 11:12: AM
via Amgen on Monday terminated the development of its investigational bispecific T-cell engager AMG 794, which it had been studying in a Phase I trial for several solid tumors including non-small cell lung cancer and epithelial ovarian cancer.

article source
 




Top Bottom
Back
Quote